CTLA4-related primary immune dysregulatory disorders

Area of Science:

• Immunology
• Genetics
• Clinical Medicine

Background:

• CTLA4-related immune disorders are primary immune dysregulation syndromes.
• These disorders involve susceptibility to infections, autoimmunity, hyperinflammation, and malignancies.
• LRBA deficiency and CTLA-4 insufficiency are key examples requiring updated clinical guidance.

Purpose of the Study:

• To review current knowledge on LRBA deficiency and CTLA-4 insufficiency.
• To guide clinicians in diagnosing and managing these CTLA4-related immune disorders.
• To highlight emerging molecular mechanisms and therapeutic strategies.

Main Methods:

• Review of recent studies on LRBA/DEF6-mediated CTLA-4 recycling.
• Analysis of novel molecular interactions (NBEAL2, Arf1-Rab4) and BEACH-domain protein function.
• Clinical data review on phenotypic heterogeneity and treatment efficacy.

Main Results:

• LRBA/DEF6 facilitates CTLA-4 recycling, crucial for immune tolerance.
• Phenotypic heterogeneity includes infections (CVID, IPEX, ALPS-like), pulmonary/neurological issues, and malignancies.
• Abatacept and sirolimus show efficacy; HSCT is curative; multiomics may personalize therapy.

Conclusions:

• Tailored immunomodulation with abatacept and sirolimus enhances disease control and quality of life.
• Early diagnosis, multidisciplinary care, and timely HSCT are vital for optimal outcomes.
• Gene therapy and AI-driven pathways offer future personalized treatment possibilities.